Introduction
============

Endoscopic ultrasound (EUS)-guided tissue sampling is a safe and accurate modality for diagnosing and staging lesions in and around the gastrointestinal tract [@JR426-1]. It enables clinicians to obtain a tissue diagnosis during real-time imaging, using fine-needle aspiration (FNA) or fine-needle biopsy (FNB). The diagnostic accuracy of these sampling techniques ranges from 52 % to 98 % and is influenced by several factors including target lesion characteristics, operator skills, needle size and type, sampling techniques, presence of an on-site pathologist, and specimen handling and processing [@JR426-2] [@JR426-3] [@JR426-4] [@JR426-5] [@JR426-6] [@JR426-7] [@JR426-8] [@JR426-9].

To provide endosonographers with some guidance, both the American and European Society of Gastrointestinal Endoscopy (ASGE and ESGE) issued a set of guidelines [@JR426-10] [@JR426-11] [@JR426-12] [@JR426-13] [@JR426-14] [@JR426-15] [@JR426-16]. In 2011, the ESGE published practice guidelines on EUS-guided tissue sampling, covering its indications, learning phase, techniques, complications, and results [@JR426-11] [@JR426-12]. They were updated in 2013, adding two new techniques; elastography and contrast enhanced ultrasound [@JR426-16]. The ASGE has issued practice guidelines concerning sedation, antibiotic prophylaxis, and prevention of adverse events. In addition, the Papanicolaou Society of Cytopathology (PSC), one of the leading societies in cancer cytopathology, published guidelines addressing EUS cytology techniques, terminology, ancillary studies, and post-procedure management [@JR426-17] [@JR426-18]. [Table 1](#TB426-1){ref-type="table"} compares their most important recommendations. Unfortunately, due to the limited number of well-conducted studies in this field, many of these recommendations lack firm scientific evidence. As a result, today's practice mainly relies on local hospital protocols, expert opinions, and personal preferences.

###### Recommendations for EUS-guided tissue sampling from the ASGE, ESGE, and Papanicolaou Society of Cytopathology.

                               ASGE                                                                                                                                                                                            ESGE                                                                                                                                              Papanicolaou Society of Cytopathology
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  **Anticoagulant use**                                                                                                                                                                                                        Check coagulation status in patients with personal or family history suggesting bleeding disorder or with a clear clinical indication.            
                               EUS-FNA of solid lesions can be performed in patients on aspirin or NSAIDS, but not in patients on thienopyridines.                                                                             EUS-FNA of solid lesions can be performed in patients on aspirin or NSAIDS, but not in patients on thienopyridines.                               
  **Antibiotic prophylaxis**   Recommended before sampling of cystic lesions.                                                                                                                                                  Recommended before sampling of cystic lesions.                                                                                                    
  **Sedation**                 Propofol provides more rapid onset of action and shorter recovery time. No proof of higher patient satisfaction or better safety. Cost-effectiveness for average-risk patients is not proven.   Propofol provides higher post-procedural patient satisfaction, decreases time to sedation and recovery. No proof of cost-effectiveness.           
                               On-site anesthesiologist suggested in presence of patient-related risk factors.                                                                                                                 On-site anesthesiologist suggested in presence of patient-related risk factors.                                                                   
  **Needle size**                                                                                                                                                                                                              19-gauge, 22-gauge and 25-gauge needles have similar diagnostic yields and safety profiles.19G should not be used for transduodenal puncturing.   Generally: 22-gauge or 25-gaugeVascular mass: 25-gaugeLymph nodes: 25-gaugeMucinous cyst: 22-gaugeFibrotic stromal rich mass: 19-gauge
  **Number of passes**                                                                                                                                                                                                         Cysts: 1Solid pancreatic: ≥ 5Lymph nodes: 3                                                                                                       Cysts: 1Solid pancreatic: 5 -- 7Lymph nodes: \< 5Stromal cell tumor: 3 -- 5
  **Suction**                                                                                                                                                                                                                  Applying continuous suction with a syringe is recommended in solid masses but not in lymph nodes.                                                 

Although EUS-guided tissue sampling is globally established, little is known about intercontinental variations in clinical practice. It is also unknown how available practice guidelines are implemented in current local sampling routines. The purpose of this study, therefore, was to: 1) map the practice patterns in EUS-guided tissue sampling in today's endosonographic community; 2) identify differences and concordances between endosonographers from the United States, Europe and Asia; and 3) compare the current practice patterns to the guidelines of the ASGE and ESGE.

Patients and methods
====================

Selection of study subjects
---------------------------

An online questionnaire was sent out per e-mail to endosonographers from the United States, Europe, and Asia. Registered endosonographers were selected by 1) using the personal network of the research team, which consists of national and international experts in the field, and 2) performing a PubMed literature search to identify authors who have published on the topic of EUS-guided tissue sampling in the last 10 years. Not only first authors but all listed authors were approached. Consent to participate in the study was inferred from voluntary completion of the survey.

Questionnaire
-------------

The survey consisted of a maximum of 65 multiple-choice questions and was designed to take less than 10 minutes to complete (**Appendix 1**) and was divided into four sections. The first part focused on demographics including gender, age, country of residence, type and size of current practice, years of experience, training and familiarity with EUS and EUS-guided tissue sampling. The second part included questions regarding peri-procedural use of anticoagulants, antibiotics, and sedation. The third part contained questions on preferred equipment and sampling techniques and whether these preferences depend upon target lesion type (pancreatic solid or cystic mass, lymph node or submucosal mass). The final part of the survey examined practice patterns regarding tissue processing and analysis.

Questionnaire administration
----------------------------

All endosonographers were approached by e-mail with a study invitation and were provided with a personal, direct link to the survey. This link was inactivated once the survey was completed. A reminder was sent by e-mail, after 2, 4, and 6 weeks. Subjects who did not respond within 4 weeks thereafter were considered to be non-respondents.

Statistical analysis
--------------------

Only completed surveys were used for data analysis. For comparison between continents, the Chi-squared or Kruskal Wallis test was applied. All reported *P* values are two-sided and a value \< 0.05 was considered to be significant. Data were analysed with SPSS 22, Statistical Package for the Social Sciences, SPSS Inc., Chicago, Illinois.

Results
=======

Demographics
------------

A total of 400 endosonographers were approached, of whom 197 responded (49 %). Eleven responses were discarded because they were incomplete, which resulted in 186 participants (47 %): 54 from the United States (29 %), 85 from Europe (46 %), and 47 from Asia (25 %, [Table 2](#TB426-2){ref-type="table"}, Appendix 2). The majority of the respondents were male (90 %) gastroenterologists (96 %), working in an academic setting (79 %), and performing \> 300 EUS (58 %) and \> 100 EUS-FNA procedures per year (68 %).

###### Demographics and practice details of survey respondents per continent.

  -----------------------------------------------------------------------------------------------------------
  Variables                               All\              US\               Europe\         Asia\
                                          n = 186 (100 %)   n = 54 (29 %)     n = 85 (46 %)   n = 47 (25 %)
  --------------------------------------- ----------------- ----------------- --------------- ---------------
  **Age, years**\[Median IQR\]             46 (41 -- 52)    44,5 (41 -- 54)   47 (41 -- 52)   43 (40 -- 49)

  **Male gender**\[Median IQR\]           168 (90)          48 (89)           77 (91)         43 (92)

  **Specialty**                                                                               

   Gastroenterology                       178 (96)          54 (100)          78 (91)         46 (98)

   Other                                    8 (4)                              7 (9)           1 (2)

  **Type of hospital**                                                                        

   Academi                                146 (78)          48 (89)           64 (76)         34 (72)

   Community                               24 (13)           2 (4)            17 (20)          5 (11)

   Other                                   16 (9)            4 (8)             4 (4)           8 (17)

  **Years of experience**\[Median IQR\]    13 (8 -- 20)     13 (5 -- 22.25)   14 (9 -- 20)    12 (8 -- 18)

  **EUS procedures/yr.**                                                                      

   \< 100                                   7 (4)            0 (0)             5 (6)           2 (4)

   100 -- 200                              33 (18)           7 (13)           11 (13)         15 (32)

   200 -- 300                              37 (20)          15 (28)           15 (18)          7 (15)

   \> 300                                 109 (58)          32 (59)           54 (63)         23 (49)

  **EUS-FNA/yr.**                                                                             

   \< 50                                   16 (9)            2 (4)             6 (7)           8 (17)

   50 -- 100                               44 (24)          11 (20)           20 (24)         13 (28)

   100 -- 200                              53 (28)          17 (32)           20 (24)         16 (34)

   \> 200                                  73 (39)          24 (44)           39 (45)         10 (21)

  **Formal EUS-training**                 114 (61)          37 (69)           48 (57)         29 (62)
  -----------------------------------------------------------------------------------------------------------

Abbrieviation: EUS, endoscopic ultrasound; FNA, fine-needle aspiration; IQR, interquartile range; US, United States

Preprocedural practice patterns
-------------------------------

### Coagulation status

In preparation for the procedure, most European (75 %) and Asian (84 %) respondents report that they "always check" coagulation status, while their US colleagues generally do so on indication ([Table 3](#TB426-3){ref-type="table"}, *P* = 0.007). Acetylsalicylic acid is generally continued (77 %), but that differed between continents. US respondents always continue acetylsalicylic acid, as compared to 87 % of European and 50 % of Asian respondents ( [Table 3](#TB426-3){ref-type="table"}, *P* \< 0.001). Regarding the use of heparin, coumarin, and new oral anticoagulants (NOACs), there is little consensus. While heparin is discontinued by all US and most Asian respondents (94 %), it is stopped by 75 % of the Europeans (*P* = 0.022). The opposite is true for coumarin, which is stopped more often in Europe (86 %) than in the United States (46 %) and Asia (59 %, *P* = 0.003). In analogy, European respondents less often perform tissue sampling in patients with an international normalized ratio (INR) \> 1.5 (11 %), as compared to non-European respondents (33 %, *P* = 0.008). Lastly, NOACs are discontinued by virtually all US (91 %) and European (88 %) endosonographers, as compared to 66 % of Asian respondents (*P* = 0.029).

###### Anticoagulation and antiplatelet management for EUS-guided tissue sampling per continent.

  ---------------------------------------------------------------------------------------------------------------------------------
  Variables                       All\         US\          Europe\      Asia\        *P* value[1](#FN426-1){ref-type="table-fn"}
                                  n = 99 (%)   n = 11 (%)   n = 56 (%)   n = 32 (%)   
  ------------------------------- ------------ ------------ ------------ ------------ ---------------------------------------------
  **Routine coagulation check**                                                       

   Always                         73 (74)       4 (36)      42 (75)      27 (84)      0.007

   On indication                  26 (26)       7 (64)      14 (25)       5 (16)      

  **Anticoagulant stopped**                                                           

   Acetylsalicylic acid           23 (23)       0 (0)        7 (13)      16 (50)       \< 0.001

   Thienopyridines                80 (81)       8 (73)      47 (84)      25 (78)      0.618

   Heparin                        83 (84)      11 (100)     42 (75)      30 (94)      0.022

   Coumarins                      72 (73)       5 (46)      48 (86)      19 (59)      0.003

   NOACs                          80 (81)      10 (91)      49 (88)      21 (66)      0.029
  ---------------------------------------------------------------------------------------------------------------------------------

Abbreviations: US, United States; NOACs, new oral anticoagulants.

A chi square test was used to compare the three continents.

### Antibiotic prophylaxis

In all continents, the majority of respondents use antibiotic prophylaxis for EUS-guided tissue sampling (77 %); mostly depending on the indication (92 %), but some use antibiotics routinely (8 %). Of those endosonographers who report prescribing antibiotics on indication, virtually all use it when sampling a cystic lesion (95 %) [@JR426-12]. A minority prescribes antibiotics for other indications, such as a prosthetic cardiac valve, vascular graft, previous infective endocarditis, or congenital heart disease (\< 39 %, [Table 4](#TB426-4){ref-type="table"}). US physicians reported the lowest use of antibiotic prophylaxis.

###### Antibiotic prophylaxis for EUS-guided tissue sampling; the United State as compared to Europe and Asia.

                                         Alln = 132 (%)   USn = 38 (%)   Europe + Asian = 94 (%)   *P* value[1](#FN426-2){ref-type="table-fn"}
  -------------------------------------- ---------------- -------------- ------------------------- ---------------------------------------------
  **Antibiotic prophylasis**                                                                       
   Prosthetic valve                      41 (31)           6 (16)        35 (37)                   0.012
   Vascular graft                        17 (13)           1 (3)         16 (17)                   0.018
   History of IE                         52 (39)           5 (13)        47 (50)                    \< 0.001
   History of CHD                        19 (14)           2 (5)         17 (18)                   0.045
   Lesion lower gastrointestinal tract   44 (33)          13 (34)        31 (33)                   0.523

Abbreviations: US, United States; IE, infectious endocarditis; CHD, congenital heart disease

A chi square test was used to compare Europe and Asia with the US.

### Sedation and anesthesia

Almost all endosonographers sedate their patients during EUS-guided tissue sampling (98 %). Propofol is generally used in the United States (83 %), whereas conscious sedation is still used by 52 % of European and 84 % of Asian respondents (*P* \< 0.001). All US respondents who use propofol have anesthesia personnel in the endoscopy room (100 %), compared to only 66 % in Europe and 50 % in Asia (*P* \< 0.001).

### Sampling techniques and equipment

#### Target lesion size

While half of the respondents perform EUS-FNA, regardless of the lesion diameter, the other half has a preferred minimum size of 0.5 cm (32 %), 1 cm (17 %), or 2 cm (1 %). For EUS-FNB, most respondents confine to a minimum size of 1 cm (59 %). European respondents perform EUS-FNB of lesions \< 1 cm more often (51 %) than non-European respondents (34 %, *P* = 0.014).

#### Needle size

The gross of respondents prefers a specific needle size for FNA (84 %) and FNB (75 %), depending on the position of the scope or the location of the target lesion (66 %). Overall, the 22-gauge needle is most popular ([Table 5](#TB426-5){ref-type="table"}). However, for FNA of solid pancreatic lesions, 22-gauge (45 %) and 25-gauge (49 %) needles are used equally, and for FNA of submucosal lesions, besides the 22-gauge (44 %), the 19-gauge needle (49 %) is frequently used. For FNB of submucosal masses, most respondents use the 19-gauge needle (62 %). Responses did not differ between continents.

###### Reported use of needle size for EUS-guided tissue sampling.

  FNA                        All n = 88 (%)   FNB                        All n = 72 (%)
  -------------------------- ---------------- -------------------------- ----------------
  Overall                                     Overall                    
   25-gauge                   86 (24)          25-gauge                   34 (12)
   22-gauge                  192 (55)          22-gauge                  150 (52)
   19-gauge                   74 (21)          19-gauge                  104 (36)
  Pancreatic cystic lesion                    Pancreatic cystic lesion   
   25-gauge                    4 (5)           25-gauge                    4 (6)
   22-gauge                   61 (69)          22-gauge                   49 (68)
   19-gauge                   33 (26)          19-gauge                   19 (26)
  Pancreatic solid lesion                     Pancreatic solid lesion    
   25-gauge                   43 (49)          25-gauge                   15 (21)
   22-gauge                   40 (46)          22-gauge                   35 (49)
   19-gauge                    5 (5)           19-gauge                   22 (31)
  Lymph node                                  Lymph node                 
   25-gauge                   33 (38)          25-gauge                   13 (18)
   22-gauge                   48 (54)          22-gauge                   41 (57)
   19-gauge                    7 (8)           19-gauge                   18 (25)
  Submucosal mass                             Submucosal mass            
   25-gauge                    6 (7)           25-gauge                    2 (2)
   22-gauge                   43 (49)          22-gauge                   25 (35)
   19-gauge                   39 (44)          19-gauge                   45 (63)

Abbreviations; FNA, fine-needle aspiration; FNB, fine-needle biopsy

#### Number of passes

Generally, respondents perform two to three needle passes for FNA (49 %) and FNB (57 %). Most respondents adjust the number of passes according to the target lesion. In pancreatic cysts, a single pass is performed for FNA (81 %) and FNB (76 %). For FNA of solid pancreatic masses, two to three (46 %) or more than three needle passes are performed (50 %). For FNB of solid pancreatic masses, most respondents report carrying out only two to three passes (70 %). A minority report doing more than three passes (26 %). Asian respondents vary their number of needle passes less often (47 %) than European (69 %) and US respondents (63 %, *P* = 0.037).

#### Sampling technique

Fanning is the preferred needle motion technique for FNA (64 %). For FNB, fanning (44 %) and only moving "to and fro" (46 %) are favored equally. To increase the yield of EUS-FNA, most endosonographers apply suction with a syringe (47 %) or use the slow-pull technique (42 %). Most respondents use dry instead of wet suction (93 %). Also for FNB, most endosonographers use an additional technique to increase the yield (70 %): slow pull (53 %), suction (44 %), or a combination (3 %). Some respondents adjust the sampling technique according to the target lesion (38 %). While the slow-pull technique is mostly used for solid pancreatic masses (58 %) and lymph nodes (62 %), suction is generally applied for pancreatic cysts (82 %) and submucosal lesions (48 %).

### Tissue processing and analysis

#### Preservation and optimization

After FNA, a majority of the endosonographers prepare glass slides (65 %), which they fixate in alcohol (45 %) or leave to air dry (43 %). As for liquid-based cytology, Cytolyt is generally used to preserve FNA specimens in the United States (50 %) and Europe (53 %), while in Asia, both saline (28 %) and alcohol (38 %) are used (*P* \< 0.001). Formalin is mostly used to preserve FNB or histologic tissue specimens (62 %). In order to increase the yield of sampling, most respondents also prepare and analyze tissue cores after FNA (73 %) or cytological material after FNB (73 %). Asian respondents more often look for tissue cores after FNA (96 %) than European (68 %) and US respondents (61 %, *P* \< 0.001).

#### ROSE

Rapid on-site pathological evaluation (ROSE) is available to 65 % of endosonographers. Virtually all US respondents use ROSE (98 %), compared to only half of respondents from Europe (48 %) and Asia (55 %, *P* \< 0.001). Reasons for omitting ROSE included "limited pathology staffing" (74 %), "disbelieve in its additive value" (32 %), "high costs" (24 %), and "additional procedure time" (24 %).

#### Ancillary techniques

The majority of respondents apply the cellblock technique (85 %). In the United States, almost all endosonographers use cellblock (96 %), while it is used to a lesser extent in Europe (85 %) and Asia (70 %, *P* = 0.002). Immunohistochemical analysis is also available for most respondents (96 %), and generally used for diagnosing and staging submucosal masses (91 %), solid pancreatic lesions (75 %) and lymph nodes (70 %).

Discussion
==========

To the best of our knowledge, no study has investigated practice trends in EUS-FNA guided tissue sampling with respect to the current ASGE and ESGE guidelines. This survey identified substantial intercontinental differences in EUS-guided tissue sampling. Interestingly, some routines vary considerably from the recommendations expressed in existing guidelines.

We found that sedation with propofol is custom in the United States, but not in Asia and Europe. In the past, conscious sedation was standard of care, but procedures have become lengthier and more complex, requiring higher doses of sedatives. Propofol is appreciated as an alternative, because it provides a deep level of sedation with a short recovery time. However, costs may be higher, due to the need of aneasthesiological assistance in most countries [@JR426-13] [@JR426-19] [@JR426-20]. Because cost-effectiveness of sedation with propofol has not been established, the American and European Society of Gastroenterology do not take a stand on this subject [@JR426-11] [@JR426-13]. Although we did not ask participants for the reasons behind their choice, previous studies have suggested that the increased use of propofol in the United States is caused by: 1) the believe that it improves the diagnostic accuracy of EUS-guided tissue sampling; 2) efforts to offset falling procedure reimbursements; and 3) marketing strategies of anesthesiologists [@JR426-13] [@JR426-21] [@JR426-22].

The second interesting finding involves differences in anticoagulation and antiplatelet management. While respondents from the United States generally check coagulation status on indication only, European and Asian respondents do this more routinely. Interestingly, the practice of the US respondents, rather than that of the Europeans, seems to follow the ESGE guidelines, which recommend checking coagulation status only in selected patients, that is, those using anticoagulant or antiplatelet therapy or who have a (family) history of a bleeding disorder. Both the ASGE and ESGE recommend not discontinuing acetylsalicylic acid, while all other anticoagulation and antiplatelet therapy should be stopped [@JR426-12] [@JR426-23]. In contrast to US respondents, not all European and Asian respondents adhere to this recommendation. One explanation might be that US physicians adhere to guidelines more promptly, possibly as a consequence of an increased chance for malpractice claims in the United States [@JR426-24] [@JR426-25]. The relatively high number of Asian respondents who discontinue acetylsalicylic acid may be a reflection of the fact that bleeding risks are weighted more heavily in Asia. It has been suggested that Asians are more susceptible to bleeding complications, while whites are more at risk for thromboembolic events [@JR426-26]. However, the Japan Gastroenterological Endoscopy Society has recently revised their guidelines, emphasizing the thromboembolism risks of discontinuation of antithrombotic agents [@JR426-27]. Therefore, a shift toward continuance of acetylsalicylic acid is to be expected.

Another interesting finding of this survey is that for solid pancreatic masses, endosonographers report performing fewer needle passes with FNB than with FNA. This finding is line with recently published data about using FNB to establish a diagnosis in solid pancreatic masses [@JR426-28] [@JR426-29] [@JR426-30] [@JR426-31]. The ESGE recommends performing at least five passes for FNA of solid pancreatic masses, in the absence of ROSE. Neither the ASGE not the ESGE recommend a minimum number of passes for FNB.

Also noteworthy is that, overall, most respondents reported using the 22-gauge needle more often than the 25-gauge needle. This finding is especially interesting, since two recent meta-analyses found no differences between the two needles, with regard to diagnostic accuracy, the number of needle passes, or complications [@JR426-8] [@JR426-32]. In fact, a trend towards better performance of the 25-gauge needle for FNA of solid pancreatic masses was observed in these studies. The ESGE guideline states that, although there is no difference in diagnostic yield and safety profiles, the 25-gauge needle performs somewhat better with regard to number of required needle passes, presumably due to its higher flexibility [@JR426-12]. The Papanicolaou Society of Cytopathology (PSC), recommends adapting the needle size to the target lesion. For highly vascular lesions and lymph nodes they recommend a 25-gauge needle, for mucinous cysts a 22-gauge needle, and for fibrotic or stromal-rich lesions, a 19-gauge needle [@JR426-17].

Another important outcome of this survey is the intercontinental variation in use of rapid on-site pathological evaluation. Whereas virtually all US respondents use ROSE, only half of the European and Asian respondents do. Respondents who refrain from using ROSE state that they consider it too time consuming and that reimbursement for pathology services is too low. However, more than two-thirds of our respondents also mention that they have doubts with regard to the added benefit of ROSE, which might be influenced by ESGE recommendations of the ESGE stating that ROSE should only be implemented at sites where specimen adequacy rates are below 90 % or during the learning curve of EUS-FNA [@JR426-12] [@JR426-33]. In contrast, the PSC recommends the use of ROSE whenever possible [@JR426-17].

The last, but certainly not least remarkable finding concerns the preservation of the tissue samples. After procurement, EUS-FNA specimens are susceptible to damage by colonizing bacteria and to autolysis by enzyme activity. To halt these processes, it must be placed in a fixative (e. g., formalin, CytoRich Red, Cytolyt) or physiologic solution (e. g., saline, Hanks' salt solution). Although most of the respondents use formalin to preserve histologic samples, there is no consensus regarding preservation of cytological samples. While a majority of the Asian respondents store cytology in alcohol or saline, their European and US colleagues store it in Cytolyt. Although there are currently no guidelines on this topic, we did not expect to find such striking differences among the three continents. It would be interesting to investigate the influence of preservation methods on the specimen's quality and diagnostic accuracy, as this aspect is under-investigated so far.

Our survey has some potential limitations. First, it seems conceivable that our results have been subject to a response bias, given our response rate of 47 %. Although our response rate still falls at the high end of the spectrum of responses for online surveys amongst physicians (1 -- 10), it might have caused a selection towards the more active, academic endosonographers. Although most respondents indeed reported to work in high-volume academic centers, only 61 % had participated in a formal EUS training program. This could have accounted for the low adherence to the practice guidelines. Currently, the ESGE and ASGE advise that a dedicated fellowship should last 6 to 24 months [@JR426-12] [@JR426-34]. However, they also acknowledge that there is a lack of sufficient EUS-training and training capacity in Europe and the United States [@JR426-35] [@JR426-36]. Because most respondents in the current study are EUS experts, the number of formally trained endosonographers and the adherence to the guidelines is likely to be even lower in non-academic, low-volume centers. Last, a reporting or goodwill bias is likely to exist, since that is inevitable for retrospective surveys that are based on self-reporting. If respondents indeed gave an expected answer rather than a true answer, that would only strengthen our main conclusion that practice patterns for EUS-guided tissue sampling differ and are not congruent with the guidelines. In conclusion, this survey shows that there is considerable intercontinental variation in the practice of EUS-guided tissue sampling. Despite of the growing number of studies in the field of EUS-guided tissue sampling, the optimal sampling strategy remains subject to debate. Moreover, some routines vary considerably from recommendations stated in existing guidelines. Further studies are required to determine the relevance and impact of various practices on outcome and safety. Pending these outcomes, cost-effectiveness studies may be required to support the implementation of a certain sampling strategies.

Appendix 1 International EUS Survey
===================================

Background Information
----------------------

**1. What is your gender?**  □ Female □ Male

**2. What is your age?**  Please write your answer here: \_\_\_\_\_\_\_\_\_

**3.What is your specialty?**  □  Gastroenterologist □  Surgeon □  Other

**4. In which year did you finish your training?**  Please write your answer here: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**5. In what country are you currently working?**  Please write your answer here: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**6. In what kind of hospital are you currently working?  (More than one option possible)**  Please choose all that apply: □ Community hospital □ Academic/University hospital □ Private hospital or independent endoscopy unit □ Other, please specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**7. How many EUS procedures do you perform each year?**  Please choose only one of the following: □ \< 100 □ 100 -- 200 □ 200 -- 300 □ \> 300

**8. How many EUS-guided tissue-sampling procedures do you  perform each year?**

 Please choose only one of the following: □ \< 50 □ 50 -- 100 □ 100 -- 200 □ \> 200

**9. Did you have formal training in performing EUS guided tissue  sampling?** *(Formal training is defined as a fellowship in a  dedicated EUS training center for at least 3 months)*  Please choose only one of the following: □ Yes □ No

Preparation for EUS guided tissue sampling
------------------------------------------

**10. Do you use any type of sedation when performing EUS-guided  tissue sampling?**  Please choose only one of the following: □ Yes, conscious sedation, continue to 12 □ Yes, propofol □ No, not as standard practice, continue to 12

**11. Is anesthesia personnel routinely present during the  procedure?**  Please choose only one of the following: □ Yes □ No

**12. Do you use antibiotic prophylaxis when performing  EUS-guided tissue sampling?**  Please choose only one of the following: □ Yes, always, continue to 14 □ Yes, depending on the indication □ No, continue to 14

**13. Please specify for which indication you use AB prophylaxis?  (More than 1 answer possible)**  Please choose all that apply: □ Cystic lesions □ Prosthetic cardiac valve □ Vascular graft □ History of previous infective endocarditis □ Congenital heart disease □ Solid lesions of lower gastrointestinal tract □ Other, please specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**14. Do you routinely check the coagulation parameters before  EUS-guided tissue sampling?**  Please choose only one of the following: □ Yes □ No, continue to 18

**15. Please specify when you check coagulation status?  (More than one answer possible)**  Please choose only one of the following: □ Always □ In patients on anticoagulants □ In patients with a (family) history of bleeding disorder

 □ In both, patients on anticoagulants and patients with a  (family) history of bleeding disorder

**16. Which of the following anticoagulants do you generally  discontinue, prior to a puncture procedure? (More than one  answers possible)**

 Please choose all that apply: □ Acetylsalicylic acid (Aspirin, Carbasalate calcium \[Ascal\],  Dipyridamole \[Persantin\]) □ Thienopyridines (Clopidogrel \[Plavix, Grepid, Iscover,  Vatoud\], Prasugrel \[Effient\]) □ Coumarin derivatives (Acenocoumarol \[Sintrom\],  Phenprocoumon \[Marcoumar, Marcumar, Falithrom\]) □ Heparin or derivatives (Warfarin \[Coumadin\], Dalteparin  \[Fragmin\], Nadroparin \[Fraxiparin\], Tinzaparin  \[Innohep\]) □ New Oral Anticoagulant drugs (NOAC) (Rivaroxaban  \[Xarelto\], Apixaban \[Eliquis\], Dabigatran \[Pradax\]) □ Other, please specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**17. Up to which INR value would you consider it safe to perform  EUS-guided tissue sampling?**  Please choose only one of the following: □ INR 1.0 □ INR 1.1 -- 1.5 □ INR 1.6 -- 2.0 □ INR \> 2.0

This section contains questions about Fine Needle Aspiration
------------------------------------------------------------

**18. What is the minimum lesion diameter for you to consider  FNA?**  Please choose only one of the following: □ No minimum □ 0.5 cm □ 1 cm □ 2 cm

**19. Do you have a preferred needle size for FNA?**  Please choose only one of the following: □ Yes □ No, continue to 21

**20. Does your preferred needle size depend on scope position  and/or location of target lesion?**  Please choose only one of the following: □ Yes, continue to 22 □ No

**21. Which needle size do you generally prefer?**  Please choose only one of the following: □ 19G □ 22G □ 25G

**22. Specify if your preferred needle size depends on:  (More than one answer possible)**  Please choose all that apply: □ Location of target lesion, □ Scope position, continue to 24

**23. Please specify your preferred needle size for the following  indications:**  Please choose the appropriate response for each item: 19G 22G 25G

 Pancreatic solid mass □ □ □

 Pancreatic cystic mass □ □ □

 Lymph node □ □ □

 Submucosal mass □ □ □

**24. Please specify your preferred needle size for the following  scope positions:**

 Please choose the appropriate response for each item: 19G 22G 25G

 Transgastric □ □ □

 Transduodenal D1 (Superior  part/Duodenal bulb) □ □ □

 Transduodenal D2  (Descending part) □ □ □

 Transduodenal D3  (Horizontal part) □ □ □

**25. Does your number of needle passes depend on the indication  for FNA?**  Please choose only one of the following: □ Yes □ No, continue to 27

**26. Please specify the number of needle passes per indication.**  Please choose the appropriate response for each item:  1 2 -- 3 \> 3

 Pancreatic solid mass □ □ □

 Pancreatic cystic mass □ □ □

 Lymph node □ □ □

 Submucosal mass □ □ □

**27. Please specify the number of needle passes you generally  perform.**  Please choose only one of the following: □ 1 □ 2 -- 3 □ \> 3

**28. What is your preferred needle movement technique during  FNA?**  Please choose only one of the following: □ To & Fro □ Fanning □ No preferred technique **29. Which additional techniques do you employ to increase the  yield of tissue sampling during FNA?**  Please choose only one of the following: □ Slow pull □ Syringe □ Wet suction □ Capillary technique □ None □ Other, please specify \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**30. How do you expel sampling material from the FNA needle?  (More than one answer possible)**  Please choose all that apply: □ Flushing with air □ Flushing with saline □ With stylet

**31. Do you use on-site pathological evaluation of the specimen?**  Please choose only one of the following: □ Yes, always □ Yes, sometimes □ No, continue to 33

**32. Please specify who performs on-site pathological evaluation.**  Please choose only one of the following: □ Pathologist □ Cytotechnician □ Myself

**33. Why are you not using on-site pathological evaluation?  (More than one answer possible)**  Please choose all that apply: □ No added benefit with regard to yield □ Costs □ Time □ Expertise □ No pathological personnel available □ Other, please specify \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**34. Do you prepare glass slides after you performed FNA?**  Please choose only one of the following: □ Yes □ No, continue to 37

**35. How do you fixate these smears?**  Please choose only one of the following: □ Air dry □ Direct fixation with alcohol □ Other, please specify \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**36. Which preservation medium do you use to collect cytology,  obtained with FNA?**  Please choose only one of the following: □ Saline □ Cytolyt □ A fixative (formalin) □ Hanks □ Alcohol □ Other, please specify \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**37. Is the cell block technique applied in your center?**  Please choose only one of the following: □ Yes □ No

**38. Do you or your pathologist routinely look for tissue cores  after FNA?**  Please choose only one of the following: □ Yes, always, continue to 40 □ Yes, depending on the target lesion □ No, continue to 44

**39. Please specify for which indication(s) you look for tissue cores  after FNA? (More than one answer possible)**  Please choose all that apply: □ Cystic pancreatic lesions (from solid components or cyst  wall) □ Solid pancreatic lesions □ Lymph nodes □ Submucosal lesion

**40. Are these tissue cores processed differently compared to the  cytological tissue sample?**  Please choose only one of the following: □ Yes □ No, continue to 44

**41. They are collected in a separate vial?**  Please choose only one of the following: □ Yes □ No

**42. They are collected in a different medium?**  lease choose only one of the following: □ Yes □ No

**43. In what medium?**  Please choose only one of the following: □ Saline □ Cytolyt □ A fixative (formalin) □ Hanks

 □ Alcohol

This section contains questions about Fine Needle Biopsy
--------------------------------------------------------

**44. What is the minimum lesion diameter for you to consider  FNB?**  Please choose only one of the following: □ No minimum □ 0.5 cm □ 1 cm □ 2 cm

**45. Do you have a preferred needle size for FNB?**  Please choose only one of the following: □ Yes, continue to 47 □ No

**46. Which needle size do you generally prefer?**  Please choose only one of the following: □ 19G □ 22G □ 25G

**47. Does your preferred needle size depend on scope position  and/or location of target lesion?**  Please choose only one of the following: □ Yes, continue to 49 □ No

**48. Which needle size do you generally prefer?**  Please choose only one of the following □ 19G □ 22G □ 25G

**49. Specify if your preferred needle size depends on:  (More than one answer possible)**  Please choose all that apply: □ Location of target lesion □ Scope position, continue to 51

**50. Please specify your preferred needle size for the following  indications:**  Please choose the appropriate response for each item:   19G 22G 25G

 Pancreatic solid mass □ □ □

 Pancreatic cystic mass □ □ □

 Lymph node □ □ □

 Submucosal mass □ □ □

**51. Please specify your preferred needle size for the following  scope positions:**  Please choose the appropriate response for each item: 19G 22G 25G

 Transgastric □ □ □

 Transduodenal D1 (Superior  part/Duodenal bulb) □ □ □

 Transduodenal D2  (Descending part) □ □ □

 Transduodenal D3  (Horizontal part) □ □ □

**52. Does your number of needle passes depend on the indication  for FNB?**  Please choose only one of the following: □ Yes □ No, continue to 54

**53. Please specify the number of needle passes per indication.**  Please choose the appropriate response for each item:  1 2 -- 3 \> 3

 Pancreatic solid mass □ □ □

 Pancreatic cystic mass □ □ □

 Lymph node □ □ □

 Submucosal mass □ □ □

**54. Please specify the number of needle passes you generally  perform.**  Please choose only one of the following: □ 1 □ 2 -- 3 □ \> 3

**55. What is your preferred needle movement technique during  FNB?**  Please choose only one of the following: □ To & Fro □ Fanning □ No preferred technique

**56. Do you use a special technique (slow pull or syringe) to  acquire tissue with the FNB needle?**  Please choose only one of the following: □ Yes, this depends on the indication □ Yes, independent of the indication, continue to 58 □ No, continue to 59

**57. Please specify per indication**

Please choose the appropriate response for each item:

Slow pull

Syringe

Wet suction

Capillary technique Other

Pancreatic solid mass □   □   □   □   □

Pancreatic cystic mass □   □   □   □   □

Lymph node □   □   □   □   □

Submucosal mass □   □   □   □   □

**58. Please specify**  Please choose only one of the following: □ Slow pull □ Syringe □ Wet suction □ Capillary technique □ Other, please specify \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**59. How do you expel sampling material from the FNB needle?  (More than one answer possible)**  Please choose all that apply: □ Flushing with air □ Flushing with saline □ With stylet

**60. Which preservation medium do you use to collect the FNB  specimen?**  Please choose only one of the following: □ Saline □ Cytolyt □ A fixative (formalin) □ Hanks □ Alcohol □ Other, please specify \_\_\_\_\_\_\_\_\_\_

**61. Is immunohistochemical analysis performed in your center?  (when sufficient sampling material is available)**  Please choose only one of the following: □ Yes, depending on the indication □ Yes, independent of the indication, continue to 63 □ No, continue to 63

**62. Please specify (More than one answer possible)**  Please choose all that apply: □ Solid pancreatic mass □ Lymph node □ Submucosal mass **63. Is a cytological sample also prepared and evaluated (i. e. glass  slide, cyto spin), in addition to the histological tissue core  specimen?**  Please choose only one of the following: □ Yes □ No, end of survey

**64. Does this depend on the needle size?**  Please choose only one of the following: □ Yes □ No, end of survey

**65. Please specify for which needle size you look for additional  cytological sample?**  Please choose all that apply: □ 19G □ 22G □ 25G

Appendix 2 List of countries of respondents
===========================================

###### List of countries of respondents.

  Countries           Number of respondents   Percentage of total (%)
  ------------------- ----------------------- -------------------------
  **Europe**                                  
   Finland              1                       0.5
   Israel               1                       0.5
   Latvia               1                       0.5
   Scotland             1                       0.5
   Belgium              2                       1.1
   Ireland              2                       1.1
   Norway               2                       1.1
   Switzerland          2                       1.1
   Sweden               3                       1.6
   Germany              7                       3.8
   Spain                9                       4.8
   France              10                       5.4
   England             13                       7.0
   Netherlands         13                       7.0
   Italy               18                       9.7
  **Asia**                                    
   Korea                1                       1.6
   India                5                       2.7
   Malaysia             5                       2.7
   China                7                       3.8
   Singapore            8                       4.3
   Japan               19                      10.2
  **North America**                           
   United States       54                      29
  TOTAL               186                     100
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